Access Partnerships

We work with a network of regional business partners, generic licensing partners, the Medicines Patent Pool and other stakeholders to expand treatment globally.

Regional Business Partners

Regional business partners serve as our on-the-ground interface with local governments, medical organizations and other stakeholders. In addition to delivering Gilead HIV and hepatitis treatments, partners are instrumental in registering medicines with regulatory authorities and assisting with medical and clinical education. 

Regional Business Partners List

  • Africphar
  • Amba Pharmaceuticals
  • Aspen Pharmacare
  • DCH Auriga
  • Delta Medical
  • Dinafa
  • Eva Pharma
  • Ferozsons Laboratories
  • Gador Pharmaceutical Exchange
  • Gador SA
  • Hydrapharm
  • Key Oncologics
  • Medical Access Uganda
  • MedImport
  • Menarini (Latin Farma)
  • MSJ Ltd. (Unicorn)
  • Mylan Pharmaceuticals
  • Oduber
  • Ombol
  • Phillips Pharmaceuticals
  • Puerto Rico Pharmaceuticals
  • Pulse Pharmaceuticals
  • Rite Chem
  • Soho
  • Stendhal
  • Sterelin Medical & Diagnostics
  • Stein Cares
  • Tridem
  • United Medical
  • Zuellig Pharma

Generic Licensees

Generic drug manufacturers in India, China and South Africa play a major role in expanding access to Gilead HIV and hepatitis medicines in developing countries. Today, 98 percent of Gilead HIV therapy used in low- and middle-income countries is produced and sold by licensees, who have applied their skills in process chemistry and large-scale manufacturing to lower prices by more than 80 percent since 2006.

HIV and HBV Medicines Generic Licensees

  • Adcock Ingram Ltd.* (South Africa)
  • Alkem Laboratories Ltd.
  • Anhui Biochem Pharmaceutical* (China)
  • Arene Lifesciences Limited*
  • Aurobindo Pharma Ltd.*
  • Cadila Healthcare Ltd.
  • Cipla Ltd.*
  • Desano Pharmaceuticals Pvt. Ltd.*
  • Dr Reddy’s Laboratories Ltd.*
  • Emcure Pharmaceuticals Ltd.*
  • Hetero Labs Ltd.*
  • Laurus Labs Ltd.*
  • Lupin Limited*
  • Macleods Pharmaceuticals Ltd*
  • Mcneil & Argus Pharmaceuticals Ltd.
  • Micro Labs Ltd.*
  • Mylan Laboratories Ltd.
  • Natco Pharma Ltd*
  • Shanghai Desano Pharmaceuticals Ltd* (China)
  • Solara Active
  • Strides Shasun Ltd.
  • Sun Pharmaceuticals Industries Ltd
  • Unimark Remedies Ltd.
  • Zhejiang Langhua Pharmaceutical Co., Ltd* (China)

*Licensed via Medicines Patent Pool

Hepatitis C Medicines Generic Licensees

  • Aurobindo Pharma Ltd.
  • Biocon Limited
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Ferozsons Laboratories Ltd (for Pakistan only)
  • Hetero Labs Ltd.
  • Laurus Labs Pvt. Ltd.
  • Magic Pharma (for Egypt only)
  • Mylan Laboratories Ltd.
  • Natco Pharma Ltd.
  • Pharmed Healthcare (for Egypt only)
  • Solara Active Pharma Sciences
  • Strides Shasun Ltd.
  • Sun Pharmaceuticals Industries Ltd

Details of Licensing Agreements:

2006 original HIV voluntary license agreement (PDF)

2011 expanded HIV / HBV voluntary and hepatitis B license agreement (PDF)

2014 original HCV voluntary license agreement (PDF)

2017 amended & restated voluntary HIV / HBV license agreement (PDF)

2017 amended & restated voluntary HCV license agreement (PDF)

In August 2012, we also signed a collaboration agreement with Indian manufacturers to facilitate the production of low-cost, high quality generic emtricitabine (FTC) for developing countries.  FTC is a component of Truvada® and Gilead’s single tablet HIV regimen Stribild®.

Medicines Patent Pool

In 2011, Gilead was the first innovator pharmaceutical company to join the Medicines Patent Pool (MPP) to expand access to its medicines through the sharing of drug patents. The MPP was established by UNITAID, a Geneva-based global health organization that works to make high-quality, life-saving treatments and diagnostics more affordable in low-income countries. Details on the Gilead-MPP license for HIV and hepatitis B medicines are available here.

Engaging Other Stakeholders

We support dialogue on global health policy. For example, since 2010, we have worked with the Wilton Park group – an agency of the UK Foreign and Commonwealth Office – to convene meetings that promote open discourse on critical issues, such as HIV and hepatitis treatment scale-up.